TerminatedPhase 4NCT05228184

Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

Studying Congenital hypothyroidism

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: IBSA Institut Biochimique SA
Principal Investigator: Giuseppe Mautone
IBSA Head of R&D Scientific Affairs
Intervention: Tirosint®-SOL(drug)
Enrollment: 34 enrolled
Eligibility: All sexes
Timeline: 2022 – 2025

Study locations (10)

Children's Hospital of Los Angeles, Los Angeles, California, United States
CHOC Children's Hospital, Orange, California, United States
University of California San Francisco, San Francisco, California, United States
Yale University, New Haven, Connecticut, United States
Children's Hospital of Atlanta, Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States
Children's Hospital Medical Center, Cincinnati, Ohio, United States
Cook Children's Health Care Systems, Fort Worth, Texas, United States

Collaborators

Cromsource

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05228184 on ClinicalTrials.gov

Other trials for Congenital hypothyroidism

Additional recruiting or active studies for the same condition.

See all trials for Congenital hypothyroidism →

← Back to all trials